Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden.
Diabetes Res Clin Pract. 2011 May;92(2):288-92. doi: 10.1016/j.diabres.2011.02.014. Epub 2011 Mar 12.
To investigate the association between oral contraceptive (OC) use and abnormal glucose regulation in Swedish middle aged women.
A prospective population-based study including 4794 women, aged 36-56 at baseline. None had previously diagnosed diabetes. At both baseline and follow-up 8 years later, the women were examined by oral glucose tolerance test. Information regarding lifestyle factors and anthropometric measurements were collected.
At baseline, current use of OCs was associated with pre (Odds ratio, OR 4.1, 95%CI 2.2-7.8) but not with type 2 diabetes. The association to prediabetes was entirely linked to IGT (OR 7.1, 3.3-15.8) in current users of OCs and in former users (OR 2.1, 1.1-3.9). Women who used OC at baseline had a better cardiovascular disease risk profile; lower body mass index (BMI), more physically active and less smoking. At follow-up, the increased risk did not persist.
Current use of OC was associated with a four times increased risk of having prediabetes and seven times of having impaired glucose tolerance. No increased risk persisted at the follow-up, suggesting that the risk due to prior use of OC is decreasing with time. The healthier lifestyle in women who used OCs may have contributed to reduced long-term risk of prediabetes.
探讨口服避孕药(OC)的使用与瑞典中年女性葡萄糖调节异常之间的关联。
一项前瞻性基于人群的研究纳入了 4794 名年龄在 36-56 岁的女性。所有参与者均无先前诊断的糖尿病。在基线和 8 年后的随访中,女性均接受口服葡萄糖耐量试验检查。收集了关于生活方式因素和人体测量学测量的信息。
基线时,当前使用口服避孕药与空腹(比值比,OR 4.1,95%CI 2.2-7.8)但与 2 型糖尿病无关。与糖尿病前期的关联完全与当前使用口服避孕药(OR 7.1,3.3-15.8)和曾经使用口服避孕药(OR 2.1,1.1-3.9)的 IGT 相关。基线时使用口服避孕药的女性具有更好的心血管疾病风险特征;较低的体重指数(BMI)、更多的身体活动和更少的吸烟。在随访中,这种风险增加并不持续存在。
当前使用口服避孕药与糖尿病前期风险增加四倍和葡萄糖耐量受损风险增加七倍相关。在随访中,没有持续存在的风险增加,这表明由于先前使用口服避孕药而导致的风险随着时间的推移而降低。使用口服避孕药的女性更健康的生活方式可能有助于降低糖尿病前期的长期风险。